Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial

D. Hong; A. Shergill; L. Bazhenova; B.C. Cho; R. Heist; V. Moreno; G.S. Falchook; M. Nagasaka; P. Cassier; B. Besse; D.W. Kim; S. Yoon; X. Le; T. Zhao; S. Atwal; E. Park; J. Lee

doi:10.1016/S0959-8049(22)00992-3

YUHSpace

BROWSE

0 223

Cited 0 times in

Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial

Authors: D. Hong ; A. Shergill ; L. Bazhenova ; B.C. Cho ; R. Heist ; V. Moreno ; G.S. Falchook ; M. Nagasaka ; P. Cassier ; B. Besse ; D.W. Kim ; S. Yoon ; X. Le ; T. Zhao ; S. Atwal ; E. Park ; J. Lee